Company news

Clinuvel Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

EMA acknowledges Clinuvel filing afamelanotide in Europe `11

March 30, 2016

Clinuvel records first A$1 million in sales

March 30, 2016

Clinuvel presents SCENESSE to global porphyria conference

March 30, 2016

Clinuvel granted Australian formulation patent

March 30, 2016

Clinuvel completes first Phase II US study

March 30, 2016

Clinuvel books European Pre-Submission Meeting for SCENESSE

March 30, 2016

Response to ASX price query

March 30, 2016

Observations from Clinuvel`s programs being presented at AAD

March 30, 2016

Clinuvel - positive results from pivotal Phase III EPP study

March 30, 2016

Clinuvel granted US topical formulation patent

March 30, 2016

Clinuvel files European MAA for SCENESSE (afamelanotide)

March 30, 2016

Clinuvel completes pre-clinical program for SCENESSE

March 30, 2016

Clinuvel commences US Phase III trial of SCENESSE

March 30, 2016

Clinuvel announces positive results of Phase II US study

March 30, 2016

Appendix 4E - Preliminary Final Report

March 30, 2016

Appendix 4D - Half Yearly Report

March 30, 2016

SCENESSE successful in Phase IIa vitiligo study

March 30, 2016

Placement

March 30, 2016

Observations from Clinuvels US vitiligo study published

March 30, 2016

Five month study follow up - SCENESSE in vitiligo (CUV102)

March 30, 2016

Clinuvel clears EMA manufacturing audit

March 30, 2016

US orphan-drug designation in Hailey-Hailey Disease

March 30, 2016

Phase II vitiligo study commences in Singapore

March 30, 2016

Media Release- Clinuvel successful in US Phase III trial

March 30, 2016

EMA review of SCENESSE extended to mid-2014

March 30, 2016

Clinuvel placement

March 30, 2016

Clinuvel declines unsolicited proposal from Retrophin

March 30, 2016

JAMA Dermatology publishes SCENESSE vitiligo study results

March 30, 2016

EMA Oral Explanation Update

March 30, 2016

Clinuvel enters a joint venture with Biotech Lab Singapore

March 30, 2016

Clinuvel accredits first European EPP expert centres

March 14, 2016

Clinuvel Placement

March 14, 2016

Clinuvel brief on European commercialisation

February 15, 2016

US FDA orphan designation received for cutaneous porphyrias

February 11, 2016

Update on North American vitiligo program for SCENESSE

February 10, 2016

TGA grants Orphan Drug Designation for SCENESSE

February 10, 2016

Swiss insurers agree to reimburse Clinuvel`s SCENESSE

February 10, 2016

SCENESSE released for European Distribution

February 10, 2016

SCENESSE Commercialisation Update

February 10, 2016

S&P DJ Indices Announces March Quarterly Review

February 10, 2016

Positive preliminary results in Singaporean vitiligo study

February 10, 2016

Phase II study starts in skin disorder Hailey-Hailey Disease

February 10, 2016

NEJM publishes Phase III SCENESSE studies

February 10, 2016

Media release - US Phase II results

February 10, 2016

Management Update

February 10, 2016

Management change and regulatory review update

February 10, 2016

Italian Medicines Agency to reimburse afamelanotide for EPP

February 10, 2016

Half Yearly Report and Accounts

February 10, 2016

First positive observations from Clinuvel`s vitiligo trial

February 10, 2016

FDA grants Clinuvel a Type C Meeting

February 10, 2016

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 62 decks. Every deck is listed under its year.